MMF Immunosuppression
Phase 1Small molecule
MMF Immunosuppression is one of 78 small molecule programs targeting Scleroderma. It is currently in Phase 1.
4
Indications
4
Total Trials
4
Active Trials
77
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
282 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Belamaf
GSKPhase 3
Fludara
SanofiPhase 3
Empliciti
Bristol-Myers SquibbPhase 3
Ninlaro
TakedaPhase 3
Keytruda
Merck & Co.Phase 3
Sarclisa
AAzienda U.S.L. 1 di Massa e Carrara
Phase 3
Biaxin
AbbViePhase 3
Xpovio
KKaryopharm Therapeutics Inc
Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Azatiq
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hepatocellular Carcinoma1 trial
Multiple Myeloma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MMF Immunosuppression. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- WWondercel Biotech (ShenZhen)